MDMA

A new market forecast projects the psychedelic drugs market to expand through 2035, driven by rising demand for mental health treatments and regulatory breakthroughs in approving psychedelic-based therapies. Industry analysts say growing acceptance of substances like psilocybin and MDMA for conditions such as depression and PTSD is attracting investment, though clinical and legal hurdles remain ahead of widespread adoption.

Researchers suggest participants' age could account for why psychedelic studies produce differing conclusions about safety and effectiveness. Older adults may respond differently to substances like psilocybin or MDMA, meaning trials skewed toward younger or older volunteers could reach inconsistent findings. The claim highlights a gap in how psychedelic research is designed and interpreted.

New research reports that a single dose of MDMA prevented trauma-fueled alcohol drinking in rats genetically predisposed to heavy drinking. The study, covered by PsyPost in 2026, adds to growing interest in MDMA-assisted therapy for trauma and addiction, with observers debating how far animal findings can translate to human treatment.

Drug-checking services in Lucerne, Switzerland, flagged a white pill stamped with a Bitcoin logo, weighing 528 mg, that was found to contain 145 mg of MDMA plus a small amount of MDEA and an unidentified substance. Public warnings like this alert users that the pill contains a notably high dose of MDMA, raising risk of overdose, especially as the extra components are unconfirmed.